Tempol treatment shows phenotype improvement in mdx mice

Author(s)

Hermes, Tulio de Almeida ^[1] ; Mancio, Rafael Dias ^[1] ; Macedo, Aline Barbosa ^[1] ; Mizobuti, Daniela Sayuri ^[1] ; da Rocha, Guilherme Luiz ^[1] ; Alves Cagnon, Valeria Helena ^[1] ; Minatel, Elaine ^[1]

Affiliation

^[1] State Univ Campinas UNICAMP, Inst Biol, Dept Struct & Funct Biol, Campinas, SP - Brazil

• Document type: Journal article
• Source: PLoS One; v. 14, n. 4 APR 22 2019.
• Web of Science Citations: 2

Abstract

Considering potential Tempol effects on mdx muscle fibers, in this study we evaluated its effects on relevant dystrophic phenotypic characteristics, such as muscle degeneration, inflammatory process and angiogenesis, which as yet have not been investigated. Mdx mice were randomly assigned into three groups: mdxS, the control group receiving intraperitoneal (i.p.) injections of saline solution (100 mu L); mdxP, positive control group receiving prednisolone (1mg/kg) by oral gavage; and mdxT, treated group receiving i.p. injections of tempol (100 mg/kg). C57BL/10 mice were also used as controls. Tempol treatment promoted gain in muscle strength and reduced myonecrosis and inflammatory response in the dystrophic diaphragm (DIA) and biceps brachii (BB) muscles. No evidence of Tempol's beneficial performance on angiogenesis in DIA and BB mdx muscles was found. The findings presented here show that Tempol treatment improves dystrophic phenotype, supporting its use as a potential therapeutic strategy in DMD. (AU)

• FAPESP's process: 14/01970-6 - Effect of Diacerein and vitamin E on dystrophic muscle fibers of mdx mice
• Grantee: Rafael Dias Mâncio
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 17/01638-0 - TEMPOL: POTENTIAL ANTIOXIDANT THERAPY FOR DYSTROPHIC MUSCULAR FIBERS
• Grantee: Elaine Minatel
• Support Opportunities: Regular Research Grants